Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

• Flow cytometry shows effective targeting of TROP2 by datopotamab deruxtecan in carcinoma samples.
• The preclinical study indicates promising activity of this antibody-drug conjugate in treating poorly differentiated endometrial carcinomas.
• TROP2 targeting may improve therapeutic outcomes in clinical applications, particularly for difficult cancer types.
• Results emphasize the need for further investigation into the clinical effectiveness of datopotamab deruxtecan.

Abstract